The meeting features the most exciting and challenging discussions on the industry’s most difficult applications including viral gene vectors and vaccines, adeno-associated virus (AAV), and other products derived with insect cell technology. Follow the link for more information: http://www.isbiotech.org/springtravel.html
Edited by Robert W. Sauerwein and Thomas L. Richie Access the journal issue here: http://www.sciencedirect.com/science/journal/0264410X/33/52 Articles citing the use of ExpreS2: Recent advances in recombinant protein-based malaria vaccines. Draper et al.
BioEurope 2015 November 2–4, 2015, Munich, Germany http://www.ebdgroup.com/bioeurope/media/about_conf.php Is your project being slowed down by protein manufacturing challenges? Try ExpreS2, a virus-free insect cell expression system, easy to scale and regulatory friendly. Meet us at BioEurope for an introductory discussion. We are sponsoring the 16th World Vaccine Congress Europe 2015 […]
The execution with Boston Children’s Hospital, located in Boston, Massachusetts, USA, of a non-exclusive research license agreement to use ExpreS2ion’s proprietary recombinant protein expression platform ExpreS2 for Boston Children’s academic research. Boston Children’s is the pediatric teaching affiliate of Harvard Medical School. Read the PR
March 2015 A vaccine against placental malaria made with ExpreS2ion® Biotechnologies protein expression technology, ExpreS2, is ready to start human tests in Germany and Benin. Placental malaria vaccine to start human tests in Germany and Benin February 2015 ExpreS2ion® Biotechnologies licenses the ExpreS2 system to the Gene Center in Munich, […]
ExpreS2ion Biotechnologies is licensed to Cancer Research UK’s Protein Purification Facility. Read the PR
EU funding for clinical trials of a placental malaria vaccine. Read the PR
ExpreS2ion Biotechnologies, Mucosis, and University of Copenhagen receive Eurostars grant for the pre-clinical development of an innovative placental malaria vaccine. Read the PR